LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Aktien・Rhythm Pharmaceuticals Inc
Search

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

87.2 -7.25

Starkes Kaufsignal

Kursupdate 11. Mai 2026, 19:59 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

86.33

Max

94.02

Schlüsselkennzahlen

By Trading Economics

Einkommen

5.4M

-48M

Verkäufe

6M

57M

Gewinnspanne

-82.974

Angestellte

414

EBITDA

5.1M

-43M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+45.24% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-565M

5.9B

Vorheriger Eröffnungskurs

94.45

Vorheriger Schlusskurs

87.2

Nachrichtenstimmung

By Acuity

72%

28%

320 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

60 / 65.58 Unterstützung & Widerstand

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Mai 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

DJ

Lesen

11. Mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

DJ

Lesen

11. Mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

DJ

Lesen

11. Mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

DJ

Lesen

11. Mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

DJ

Lesen

11. Mai 2026, 22:32 UTC

Ergebnisse

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

DJ

Lesen

11. Mai 2026, 22:02 UTC

Market Talk
Wichtige Nachrichtenereignisse

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

DJ

Lesen

11. Mai 2026, 21:49 UTC

Ergebnisse

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

DJ

Lesen

11. Mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

DJ

Lesen

11. Mai 2026, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

DJ

Lesen

11. Mai 2026, 21:23 UTC

Akquisitionen, Fusionen, Übernahmen

CSG Systems Sale to NEC Gets CFIUS Clearance

DJ

Lesen

11. Mai 2026, 21:12 UTC

Ergebnisse

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

DJ

Lesen

11. Mai 2026, 21:12 UTC

Ergebnisse

Ovintiv 1Q Loss/Shr $2.35 >OVV

DJ

Lesen

11. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Lesen

11. Mai 2026, 20:44 UTC

Ergebnisse

Steris: Board Approves New $1B Shr Repurchase Program >STE

DJ

Lesen

11. Mai 2026, 20:43 UTC

Ergebnisse

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

DJ

Lesen

11. Mai 2026, 20:32 UTC

Ergebnisse

CleanSpark 2Q Loss/Shr $1.52 >CLSK

DJ

Lesen

11. Mai 2026, 20:32 UTC

Ergebnisse

CleanSpark 2Q Rev $136.4M >CLSK

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Cont Ops EPS $2.24 >STE

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Rev $1.6B >STE

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Adj EPS $2.83 >STE

DJ

Lesen

11. Mai 2026, 20:22 UTC

Heiße Aktien

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

DJ

Lesen

11. Mai 2026, 19:37 UTC

Ergebnisse

More Bad News at KKR's Private Credit Fund -- Barrons.com

DJ

Lesen

11. Mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

DJ

Lesen

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

45.24% Vorteil

12-Monats-Prognose

Durchschnitt 136.77 USD  45.24%

Hoch 158 USD

Tief 105 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

14

Buy

0

Halten

0

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Rhythm Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

60 / 65.58Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Mittelfristig

Bullish Evidence

All events are bullish.

Langfristig

Bullish Evidence

Recent bullish events outweigh bearish events.

Stimmung

By Acuity

320 / 346 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Andere Aktien aus dem Sektor

LLY

Eli Lilly and Co.

966.35

↑ +1.98%

JNJ

Johnson and Johnson

221.39

↑ +0.12%

ABBV

AbbVie Inc

202.82

↑ +0.84%

UNH

UnitedHealth Group Inc

384.32

↑ +1.29%

AZN

AstraZeneca PLC

181.82

↓-0.27%
help-icon Live chat